Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Products In Brief

This article was originally published in The Gray Sheet

Executive Summary

Bausch & Lomb gets approval for first-of-a-kind intraocular lens. Roche HbA1c assay is first to be cleared to diagnose diabetes. More product launches and approvals from the past week.

You may also be interested in...

Final Class II Order, Special Controls For Hemoglobin A1c Tests Set

FDA spells out the special controls needed for class II specification of hemoglobin A1c test systems in a final order taking effect Sept. 24.

Hologic’s Tomosynthesis Improves Cancer Detection Rates Of Mammography In Study

3D breast tomosynthesis improves the recall rate and cancer-detection rate of mammography, according to a retrospective study of 454,850 examinations. The results may be good news for Hologic, which has struggled to accelerate adoption for the technology due to lack of reimbursement.

Thoratec Warns Of Potentially Lethal Complications When Patients Switch To New HeartMate II Controller

Serious adverse events have been linked to patients struggling to switch their Thoratec HeartMate II left-ventricular assist devices from an older controller system to the newer Pocket Controller system. The company is updating the labeling and training materials for the system and warning doctors and patients to communicate to ensure they understand how to convert to the Pocket Controller.

Related Content


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts